natgillin/translations-raw huggingface dataset:
Each 1 ml vial contains 100 μg ziconotide (as acetate).
Ena 1 ml viala vsebuje 100 µg zikonotida (v obliki acetata).
Each 5 ml vial contains 500 μg ziconotide (as acetate).
Ena 5 ml viala vsebuje 500 µg zikonotida (v obliki acetata).
Prialt was stable for 60 days at 37°C in the Synchromed pump previously exposed to the medicinal product.
V Synchromed črpalki, ki je bila prej že izpostavljena zdravilu, je bilo zdravilo Prialt stabilno 60 dni pri 37 °C.
How to store Prialt
Shranjevanje zdravila Prialt
Each vial contains 200 micrograms ziconotide (as acetate).
Ena viala vsebuje 200 mikrogramov zikonotida (v obliki acetata).
Range aResponders were defined as those patients who 1) experienced a ≥ 30% drop in VASPI score compared to baseline; 2) had stable or decreased concomitant opioid analgesics; and 3) had opiate type unchanged from preinfusion if receiving opiates.
vrednosti glede na izhodiščno vrednost, 2) imeli stabilno ali zmanjšano potrebo po opiatnih analgetikih in 3) v primeru, da so prejemali opiate, niso spremenili tipa opiatov b164 bolnikov je ob koncu titracije podalo VASPI vrednosti za zikonotid SD - standardna deviacija
- Each 20 ml vial contains 500 micrograms ziconotide (as acetate).
Ena 20-ml viala vsebuje 500 mikrogramov zikonotida (v obliki acetata).
- One ml solution contains 25 micrograms ziconotide (as acetate).
En mililiter raztopine vsebuje 25 mikrogramov zikonotida (v obliki acetata).
The solution should not be used if discoloured or cloudy or if particulate matter is observed.
V primeru spremembe barve, motnosti ali prisotnosti delcev se raztopina ne sme uporabiti.
Each 20 ml vial contains 500 μg ziconotide (as acetate).
Ena 20 ml viala vsebuje 500 µg zikonotida (v obliki acetata).
Fluid matrix
način aplikacije tekoči matriks število bolnikov
- One ml solution contains 100 micrograms ziconotide (as acetate).
- En mililiter raztopine vsebuje 100 mikrogramov zikonotida (v obliki acetata).
Each vial contains 100 micrograms ziconotide (as acetate).
Ena viala vsebuje 100 mikrogramov zikonotida (v obliki acetata).
Each ml contains 100 micrograms ziconotide (as acetate).
En ml raztopine vsebuje 100 mikrogramov zikonotida (v obliki acetata).
Examination of the patency of the intrathecal catheter should be considered if the required ziconotide dose continually increases and there is no benefit or increase in adverse reactions.
Če potrebni odmerek zikonotida kontinuirano narašča in ni ustreznega učinka oziroma več neželenih učinkov, je potrebno prekontrolirati prehodnost intratekalnega katetra.
NAME OF THE MEDICINAL PRODUCT Prialt 100 micrograms/ml solution for infusion ziconotide
Prialt 100 mikrogramov/ml raztopina za infundiranje zikonotid
NAME OF THE MEDICINAL PRODUCT Prialt 25 micrograms/ml solution for infusion ziconotide
Prialt 25 mikrogramov/ml raztopina za infundiranje zikonotid
Ziconotide (n = 169)b
Načrt začetnega zdravljenja parameter zikonotid (n = 169)b placebo (n = 86)
NAME OF THE MEDICINAL PRODUCT Prialt 25 μg/ml solution for infusion ziconotide
Prialt 25 µg/ml raztopina za infundiranje zikonotid
No clinical data are available on the interaction between IT chemotherapy and IT ziconotide.
Le malo bolnikov je prejemalo sistemsko obliko kemoterapije in IT zikonotid.
Ziconotide (n = 112)
Načrt začetnega zdravljenja parameter zikonotid (n = 112)
Intravenous
Dojenje
What Prialt looks like and contents of the pack Prialt is a solution for infusion (infusion).
Zdravilo Prialt je raztopina za infundiranje (infuzija).
_ _1 Neisseria meningitidis serogroup A polysaccharide* 5 micrograms Neisseria meningitidis serogroup C polysaccharide* 5 micrograms Neisseria meningitidis serogroup W-135 polysaccharide* 5 micrograms Neisseria meningitidis serogroup Y polysaccharide* 5 micrograms *conjugated to tetanus toxoid carrier protein 44 micrograms
1 viala + 1 ampula polisaharid Neisseria meningitidis serološke skupine A* 5 mikrogramov polisaharid Neisseria meningitidis serološke skupine C* 5 mikrogramov polisaharid Neisseria meningitidis serološke skupine W-135* 5 mikrogramov polisaharid Neisseria meningitidis serološke skupine Y* 5 mikrogramov
(Invented) name
Številka EU (Izmišljeno) ime
1 vial + 1 prefilled syringe
1 viala + 1 napolnjena injekcijska brizga
10 vials + 10 pre-filled syringes + 20 needles
10 napolnjenih injekcijskih brizg + 20 igel
1 vial + 1 ampoule
10 vial +
MA (EU) number (Invented) name
Številka EMA (Izmišljeno) ime Jakost
Ref.: EMEA/619504/2009 EMEA/H/C/1071
: EMEA/619502/2009 EMEA/H/C/1071
It is used on its own to treat patients with:
Uporablja se kot samostojno zdravilo za zdravljenje bolnikov z:
Topotecan Teva topotecan EPAR summary for the public
Topotecan Teva topotekan Povzetek EPAR za javnost
For more information on generic medicines, see the question-and-answer document here.
Za več informacij o generičnih zdravilih si oglejte dokument z vprašanji in odgovori, ki je na voljo tukaj .
It is also used together with cisplatin (another anticancer medicine) to treat women with cervical cancer (cancer of the cervix), when the cancer has come back after radiotherapy, or when the disease is at an advanced stage (stage IVB: the cancer has spread beyond the cervix).
Zdravilo se uporablja tudi skupaj s cisplatinom (drugim zdravilom proti raku) za zdravljenje žensk z rakom materničnega vratu, če se je rak znova pojavil po že končanem zdravljenju z obsevanjem ali če je bolezen v naprednem stadiju (stadiju IVB: rak se je razširil zunaj materničnega vratu).
• metastatic cancer of the ovary (when the cancer has spread to other parts of the body).
• metastatskim rakom jajčnikov (rakom, ki se je razširil na druge dele telesa).
The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Topotecan Teva has been shown to be comparable to Hycamtin.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Topotecan Teva primerljivo z zdravilom Hycamtin.
This means that Topotecan Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Hycamtin.
To pomeni, da je zdravilo Topotecan Teva podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Hycamtin.
Topotecan Teva is given as an infusion lasting 30 minutes every day for five days with a three-week interval between the start of each course.
Zdravilo Topotecan Teva se daje z infuzijo, ki traja po 30 minut dnevno, v ciklih po pet zaporednih dni in s tritedenskimi presledki med začetki vsakega cikla zdravljenja.
The patient's blood levels of white blood cells, platelets and haemoglobin should be checked before treatment, to ensure that they are above set minimum levels.
Pred zdravljenjem je treba preveriti ravni belih krvnih celic, trombocitov in hemoglobina bolnika za zagotovitev, da te presegajo najnižje določene ravni.
Other information about Topotecan Teva:
Druge informacije o zdravilu Topotecan Teva:
What are the benefit and risk of Topotecan Teva?
Kakšne so koristi in tveganja, povezana z zdravilom Topotecan Teva?
Treatment with Topotecan Teva should only be given under the supervision of a doctor experienced in the use of chemotherapy.
Zdravljenje z zdravilom Topotecan Teva lahko poteka samo pod nadzorom zdravnika z izkušnjami na področju kemoterapije.
Because Topotecan Teva is a generic medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Ker je zdravilo Topotecan Teva generično zdravilo, se šteje, da so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
Topotecan Teva is a ‘generic medicine'.
Topotecan Teva je „generično zdravilo“.
The dose of Topotecan Teva to be used depends on the type of cancer that it is being used to treat and the patient's weight and height.
Odmerek zdravila Topotecan Teva je odvisen od vrste raka, ki ga zdravimo, in bolnikove telesne mase in višine.
When used with cisplatin in cervical cancer, Topotecan Teva is given on days 1, 2 and 3 (with cisplatin given on day 1).
Kadar zdravilo Topotecan Teva uporabljamo skupaj s cisplatinom za zdravljenje raka materničnega vratu, ga dajemo na 1., 2. in 3. dan (cisplatin dajemo na 1. dan).
The Committee recommended that Topotecan Teva be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Topotecan Teva odobri dovoljenje za promet.
Because Topotecan Teva is a generic medicine, the company has provided data from the published literature on topotecan.
Ker je zdravilo Topotecan Teva generično zdravilo, je družba predložila podatke iz objavljene literature o učinkovini topotekan.
Topotecan Teva also affects non-cancer cells, which causes side effects.
Zdravilo Topotecan Teva vpliva tudi na nerakave celice, kar povzroča neželene učinke.
The active substance in Topotecan Teva, topotecan, is an anticancer medicine that belongs to the group ‘topoisomerase inhibitors'.
Zdravilna učinkovina v zdravilu Topotecan Teva, topotekan, je zdravilo proti raku, ki spada v skupino zaviralcev topoizomeraze.
• small cell lung cancer, when the cancer has relapsed (come back).
• za zdravljenje ob relapsu drobnoceličnega pljučnega raka (ponovitvi bolezni).
The European Commission granted a marketing authorisation valid throughout the EU for Topotecan Teva to Teva Pharma B.V. on 21 September 2009.
Evropska komisija je dovoljenje za promet z zdravilom Topotecan Teva, veljavno po vsej Evropski uniji, odobrila družbi Teva Pharma B.V.
Why has Topotecan Teva been approved?
Zakaj je bilo zdravilo Topotecan Teva odobreno?
Topotecan Teva is an anticancer medicine.
Topotecan Teva je zdravilo proti raku.
It contains the active substance topotecan.
Zdravilo vsebuje zdravilno učinkovino topotekan.
Topotecan Teva is a concentrate that is made up into a solution for infusion (drip into a vein).
Zdravilo Topotecan Teva je koncentrat za pripravo raztopine za infundiranje (kapalne infuzije v veno).
The full EPAR for Topotecan Teva can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Topotecan Teva je na voljo tukaj.
The doses may need to be adjusted or other medicines given to the patients, when the level of white blood cells remains particularly low.
Če je raven belih krvnih celic še posebno nizka, moramo odmerke prilagoditi ali bolniku začeti dajati druga zdravila.
What is Topotecan Teva?
Kaj je zdravilo Topotecan Teva?
How has Topotecan Teva been studied?
Kako je bilo zdravilo Topotecan Teva raziskano?
No additional studies were needed as Topotecan Teva is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Hycamtin.
Zdravilo Topotecan Teva je generično zdravilo, ki se daje z infundiranjem in vsebuje isto zdravilno učinkovino kot referenčno zdravilo, Hycamtin, zato niso bile potrebne nobene dodatne študije.
What is Topotecan Teva used for?
Za kaj se zdravilo Topotecan Teva uporablja?
How is Topotecan Teva used?
Kako se zdravilo Topotecan Teva uporablja?
How does Topotecan Teva work?
Kako zdravilo Topotecan Teva deluje?
Baxter Hungary Kft. Népfürdő u. 22.
Madžarskem Baxter Hungary Kft. Népfürdö u. 22.
Baxter Polska SP. z o.o.
Poljskem Baxter Polska SP. z.o.o.
Baxter d.o.o., Zelezna cesta 18, Ljubljana, SI-1000, Slovenia
Slovenija Baxter d.o.o., Zelezna cesta 18 ,Ljubljana, SI-1000, Slovenia
Iceland
Islandijo
Sverige
Švedsko
Denmark
Dansko
Unterschleißheim
Farmacevtska oblika
The standard dose of Clopidogrel Acino Pharma is one 75 mg tablet once a day, taken with or without food.
Običajni odmerek zdravila Clopidogrel Acino Pharma je ena 75-miligramska tableta enkrat na dan, ki se vzame s hrano ali brez nje.
Clopidogrel Acino Pharma is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).
Zdravilo Clopidogrel Acino Pharma se uporablja pri odraslih za preprečevanje aterotrombotičnih dogodkov (težav, ki jih povzročajo krvni strdki in otrdelost krvnih žil).
This means that Clopidogrel Acino Pharma is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
To pomeni, da je zdravilo Clopidogrel Acino Pharma podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Plavix.
The European Commission granted a marketing authorisation valid throughout the EU for Clopidogrel Acino Pharma to Acino Pharma GmbH on 21 September 2009.
Evropska komisija je dovoljenje za promet z zdravilom Clopidogrel Acino Pharma, veljavno po vsej Evropski uniji, odobrila družbi Acino Pharma GmbH dne 21. septembra 2009.
The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Clopidogrel Acino Pharma has been shown to have comparable quality and to be bioequivalent to Plavix.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Clopidogrel Acino Pharma primerljivo raven kakovosti kot zdravilo Plavix ter da mu je biološko enakovredno.
Because Clopidogrel Acino Pharma is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Ker je zdravilo Clopidogrel Acino Pharma generično zdravilo in je biološko enakovredno referenčnemu zdravilu, velja, da so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
Clopidogrel Acino Pharma can be given to the following groups of patients:
Zdravilo Clopidogrel Acino Pharma se lahko daje naslednjim skupinam bolnikov:
Clopidogrel Acino Pharma can be started between seven days and six months after the stroke;
Zdravilo Clopidogrel Acino Pharma se lahko začne jemati od sedem dni po napadu do šest mesecev po njem;
Other information about Clopidogrel Acino Pharma:
Druge informacije o zdravilu Clopidogrel Acino Pharma:
Because Clopidogrel Acino Pharma is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Ker je zdravilo Clopidogrel Acino Pharma generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Plavix.
Clopidogrel Acino Pharma clopidogrel EPAR summary for the public
Clopidogrel Acino Pharma klopidogrel Povzetek EPAR za javnost
Clopidogrel Acino Pharma can be started between a few days and 35 days after the attack;
Pharma se lahko začne jemati od nekaj dni po napadu do 35 dni po njem;
The Committee recommended that Clopidogrel Acino Pharma be given marketing authorisation.
Odbor je zato priporočil, da se za zdravilo Clopidogrel Acino Pharma odobri dovoljenje za promet.
Clopidogrel Acino Pharma is a ‘generic medicine'.
Clopidogrel Acino Pharma je „generično zdravilo“.
What are the benefit and risk of Clopidogrel Acino Pharma?
Kakšne so koristi in tveganja, povezana z zdravilom Clopidogrel Acino Pharma?
Clopidogrel Acino Pharma is a medicine that contains the active substance clopidogrel.
Clopidogrel Acino Pharma je zdravilo, ki vsebuje zdravilno učinkovino klopidogrel.
The active substance in Clopidogrel Acino Pharma, clopidogrel, is an inhibitor of platelet aggregation.
Zdravilna učinkovina v zdravilu Clopidogrel Acino Pharma, klopidogrel, je zaviralec agregacije trombocitov.
The full EPAR for Clopidogrel Acino Pharma can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Clopidogrel Acino Pharma je na voljo tukaj.
Why has Clopidogrel Acino Pharma been approved?
Zakaj je bilo zdravilo Clopidogrel Acino Pharma odobreno?
How has Clopidogrel Acino Pharma been studied?
Kako je bilo zdravilo Clopidogrel Acino Pharma raziskano?
What is Clopidogrel Acino Pharma?
Kaj je zdravilo Clopidogrel Acino Pharma?
What is Clopidogrel Acino Pharma used for?
Za kaj se zdravilo Clopidogrel Acino Pharma uporablja?
How is Clopidogrel Acino Pharma used?
Kako se zdravilo Clopidogrel Acino Pharma uporablja?
How does Clopidogrel Acino Pharma work?
Kako zdravilo Clopidogrel Acino Pharma deluje?
This summary was last updated in July 2019.
Povzetek je bil nazadnje posodobljen julija 2019.
All these signs resolve spontaneously within 24 hours.
Vsi ti znaki spontano izzvenijo v 24 urah.
Contact with the applicator should be avoided.
Preprečiti je treba stik z aplikatorjem.
Consequently, it is recommended that recently treated animals do not sleep with owners, especially children.
Posledično je priporočljivo, da nedavno zdravljene živali ne spijo z lastniki, predvsem ne z otroci.
Other information about Broadline
Druge informacije o zdravilu Broadline
The European Medicine Agency decided that Broadline's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je odločila, da so koristi zdravila Broadline večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Broadline received a marketing authorisation valid throughout the EU on 4 December 2013.
Zdravilo Broadline je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 4. decembra 2013.
Further information on Broadline can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/broadline.
Nadaljnje informacije o zdravilu Broadline so na voljo na spletni strani agencije: ema.europa.eu/medicines/veterinary/EPAR/broadline.
This means that they kill parasites that live inside the body of animals.
To pomeni, da uničita parazite, ki živijo v telesu živali.
Broadline must not be used in sick or recovering animals.
Zdravilo Broadline se ne sme uporabljati pri bolnih ali okrevajočih živalih.
The product is to be used only when all three groups of parasites are targeted at the same time.
Zdravilo se sme uporabiti samo, kadar je namen zdravljenja sočasna odstranitev vseh treh skupin parazitov.
Fipronil kills adult parasites.
Fipronil uničuje odrasle parazite.
People applying the medicine should not smoke, eat or drink while doing so and should wash their hands after handling the product.
Med dajanjem zdravila se ne sme kaditi, jesti ali piti, zatem pa si je treba temeljito umiti roke.
What are the risks associated with Broadline?
Kakšna tveganja so povezana z zdravilom Broadline?
It must not be used in rabbits or in cases of hypersensitivity (allergy) to any of the ingredients.
Ne sme se uporabljati pri kuncih ali v primerih preobčutljivosti za (alergije na) katero koli sestavino zdravila.
Handling of treated animals should be limited until the application site is dry and children should not play with treated animals during this period.
Rokovanje z zdravljenimi živalmi mora biti omejeno, dokler se mesto nanosa ne posuši, otroci pa se v tem času ne smejo igrati z zdravljenimi živalmi.
An overview of Broadline and why it is authorised in the EU
Pregled zdravila Broadline in zakaj je odobreno v EU
Why is Broadline authorised in the EU?
Zakaj je bilo zdravilo Broadline odobreno v EU?
Broadline was 100% effective against the L4 larval stage of heartworm.
Zdravilo Broadline je bilo 100-odstotno učinkovito proti stadiju L4 ličinke srčne gliste.
People with known hypersensitivity to any of the ingredients should avoid contact with the product.
Osebe z znano preobčutljivostjo za katero koli sestavino zdravila naj se izogibajo stiku z njim.
What is Broadline and what is it used for?
Kaj je zdravilo Broadline in za kaj se uporablja?
This means that they kill external parasites that live on the skin or in the fur of animals, such as fleas and ticks.
To pomeni, da uničita zunanje parazite, ki živijo na koži ali dlaki živali, kot so bolhe in klopi.
It may also be used as part of a treatment strategy for flea allergy dermatitis (an allergic reaction to flea bites).
Uporablja se lahko tudi kot del strategije zdravljenja alergijskega dermatitisa, ki ga povzročajo bolhe (alergijske reakcije na ugrize bolh).
What benefits of Broadline have been shown in studies?
Kakšne koristi je zdravilo Broadline izkazalo v študijah?
If the cat licks the application site, temporary excessive salivation may occur.
Če mačka liže mesto nanosa, se lahko pojavi začasno čezmerno slinjenje.
For more information about using Broadline, see the package leaflet or contact your veterinarian or pharmacist.
Za več informacij glede uporabe zdravila Broadline glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
If a cat swallows the medicine, it may result in vomiting (being sick) and/or short-lived effects on the nervous system, shown by signs such as lack of muscular coordination, disorientation, lack of interest in surroundings and pupil dilation.
Če mačka zdravilo zaužije, lahko to povzroči bruhanje (slabost) in/ali kratkotrajne učinke na živčevje, ki se kažejo z znaki, kot so odsotnost mišične koordinacije, izguba orientacije, zmanjšanje zanimanja za okolico in razširjene zenice.
The measure of effectiveness was reduction of the number of Notoedres cati mites found in skin scrapings compared to cats that received no treatment.
Merilo učinkovitosti je bilo zmanjšanje števila srbcev rodu Notoedres cati, najdenih v odluščeni koži, v primerjavi s številom srbcev pri mačkah, ki niso prejemale zdravljenja.
For external parasites, Broadline treats flea infestations and prevents new infestations for at least one month; it also prevents environmental flea contamination for over a month.
V zvezi z zunanjimi paraziti zdravilo Broadline zdravi infestacije z bolhami in preprečuje pojav novih še vsaj en mesec; prav tako več kot mesec dni preprečuje kontaminacijo okolja z bolhami.
The study showed over 98% effectiveness of the medicine against the mite, with a clinical cure in all animals.
Študija je pokazala več kot 98-odstotno učinkovitost zdravila proti garjam s klinično ozdravitvijo pri vseh živalih
Effectiveness was measured by identifying adult worm segments (tapeworms) or counting worm eggs (roundworms) in faeces at day 14 after treatment.
Učinkovitost so merili z ugotavljanjem segmentov odraslih črvov (trakulj) ali štetjem jajčec črvov (valjastih črvov) v blatu 14. dan po zdravljenju.
For lungworm a second treatment may be recommended one month after the initial treatment.
V primeru pljučnih glist se priporoča ponovitev zdravljenja en mesec po prvotnem nanosu zdravila.
(S)-methoprene is an insect growth regulator which stops the flea life cycle by killing eggs and blocking the development of juvenile flea stages and causing their death.
(S)-metopren je sredstvo za uravnavanje rasti žuželk, ki zaustavi življenjski cikel bolh tako, da uniči njihova jajčeca in zavira razvoj nezrelih bolh, kar povzroči njihov pogin.
For ticks, effectiveness was between 85 and 93% for Broadline-treated cats compared with 92 and 98% for cats treated with the comparator product.
Pri klopih je bila učinkovitost zdravila Broadline med 85- in 93-odstotna v primerjavi z med 92- in 98-odstotno učinkovitostjo pri mačkah, zdravljenih s primerjalnim zdravilom.
Broadline was more than 90% effective in reducing lungworm larvae at 28 days after treatment and all treated cats showing respiratory signs (such as wheezing, persistent coughing and a runny nose) were clinically cured.
Zdravilo Broadline je pokazalo več kot 90-odstotno učinkovitost pri zmanjšanju števila ličink pljučnih glist na 28. dan po zdravljenju, vse zdravljene mačke, ki so kazale simptome težav z dihali (sopihanje, trdovraten kašelj in izcedek iz nosu), so bile klinično ozdravljene.
Praziquantel acts on the cell membranes of tapeworms, leading to the death of the parasite.
Prazikvantel učinkuje na celične membrane trakulj in s tem povzroči smrt parazita.
The main measure of effectiveness was reduction of numbers of worm larvae in faeces at 28 days after single treatment.
Glavno merilo učinkovitosti je bilo zmanjšanje števila ličink gliste v izločkih na 28. dan po enkratnem zdravljenju.
The study showed effectiveness of 86 to 87% against adult fleas for Broadline throughout the 30 day post-treatment period compared with between 76 and 82% for cats treated with another medicine containing just fipronil and (S)-methoprene.
Študija v EU je pokazala med 86- in 87-odstotno učinkovitost zdravila Broadline proti odraslim bolham v celotnem tridesetdnevnem obdobju po uporabi zdravila v primerjavi z med 76- in 82-odstotno učinkovitostjo pri mačkah, zdravljenih z drugim zdravilom, ki je vsebovalo samo fipronil in (S)-metopren.